✨ Free AI Report
BenevolentAI: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BenevolentAI
Research Preview

BenevolentAI: Business Overview, Financials & Competitive Analysis

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. The company develops its own in-house pipeline of drug candidates...

Analyst-debate audio for BenevolentAI

AskCyborg analysts argue the bull and bear cases for BenevolentAI across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BenevolentAI OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

BenevolentAI is a differentiated AI drug discovery platform with pharma validation and partnership revenue that is repositioning...

Read the full analyst-debate transcript →
Industry Clinical AI & Drug Discovery
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest BenevolentAI Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BenevolentAI Overview

Pro stress-test →

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. The company develops its own in-house pipeline of drug candidates across therapeutic areas like immunology, neurology, and oncology, engages in discovery collaborations with major pharmaceutical companies including multi-year agreements with AstraZeneca and Merck KGaA valued at up to $594 million. Its AI platform identified baricitinib as a potential Covid-19 treatment within 48 hours, a drug that went on to save lives globally.

Strategic Profile

Pro stress-test →

BenevolentAI is exploring a Software-as-a-Service (SaaS) model, offering its knowledge exploration tools to external partners. The company closed its US office in New York and is focusing its efforts from Cambridge and London to optimise growth opportunities. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, maintaining successful collaborations with AstraZeneca and leading research institutions.

Competitive Landscape

Pro stress-test →

BenevolentAI's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. The company differentiates through validated AI platform efficacy, major pharma partnerships, and a maturing drug pipeline. Competitors range from computational chemistry platforms to AI-first biotech companies pursuing similar drug discovery acceleration.

Industry Context

BenevolentAI operates in Clinical AI & Drug Discovery.

Key facts

Founded: 2013 · Headquarters: London, UK · Employees: 69 · Revenue: $25.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for BenevolentAI.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BenevolentAI has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SchrodingerPhysics-based computational platform for drug discovery and materials science→Recursion PharmaceuticalsAI-powered phenotypic drug discovery platform→XtalPiAI-driven drug discovery and molecular design platform→AtomwiseAI-based small-molecule drug candidate design using deep learning→InsitroMachine learning and high-throughput biology for data-driven drug discovery→

Compare BenevolentAI with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BenevolentAI operates in Clinical AI & Drug Discovery. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical AI & Drug Discovery research →
NEW · MCP server

Ask your AI assistant about BenevolentAI

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BenevolentAI and its top competitor on Cyborg Score”
“What did BenevolentAI do this quarter?”
“Is BenevolentAI a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BenevolentAI do?+
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. The company develops its own in-house pipeline of drug candidates...
What is BenevolentAI's Cyborg Score?+
BenevolentAI has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BenevolentAI's main competitors?+
Named competitors include Schrodinger, Recursion Pharmaceuticals, XtalPi, Atomwise. The full competitive landscape is in the AskCyborg report.
How can I get the full BenevolentAI research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BenevolentAI research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BenevolentAI over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.